Search Results - "Burris HA"

Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.

Authors: Burris HA Jones SF Shipley D et al.

Source: Cancer Investigation. 2010 May, Vol. 120 Issue 5, p408-412. 5p.

Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgin's lymphoma: results of four multicancer, double-blind, randomized phase II studies.

Authors: Burris HA III Belani CP Kaufman PA et al.

Source: Journal of Oncology Practice. May2010, Vol. 6 Issue 3, p133-140. 8p.

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.

Authors: Hainsworth JD Spigel DR Burris HA 3rd et al.

Source: Cancer (0008543X). 5/15/2010, Vol. 116 Issue 10, p2448-2454. 7p.

Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.

Authors: Hainsworth JD Spigel DR Burris HA 3rd et al.

Source: Cancer (0008543X). 5/15/2009, Vol. 115 Issue 10, p2138-2146. 9p.

Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer.

Authors: Kolesar JM Kuhn JG Burris HA 3rd et al.

Source: JNCI: Journal of the National Cancer Institute. 7/5/95, Vol. 87 Issue 13, p1022-1024. 3p.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors: Baselga J Campone M Piccart M et al.

Source: New England Journal of Medicine. 2/9/2012, Vol. 366 Issue 6, p520-529. 10p.

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma.

Authors: Hainsworth JD Infante JR Spigel DR et al.

Source: Cancer Investigation. Aug2011, Vol. 29 Issue 7, p451-455. 5p.

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.

Authors: Hainsworth JD Infante JR Spigel DR et al.

Source: Cancer (0008543X). 9/1/2010, Vol. 116 Issue 17, p4122-4129. 8p.

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.

Authors: Swanton C Madison RW Tambaoan CFB et al.

Source: Molecular oncology [Mol Oncol] 2025 Nov; Vol. 19 (11), pp. 3060-3078. Date of Electronic Publication: 2025 May 28.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE

Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials.

Authors: Sturgill E Jones C Burris HA 3rd et al.

Source: JCO oncology practice [JCO Oncol Pract] 2026 Jul 01, pp. OP2500922. Date of Electronic Publication: 2026 Jul 01.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Authors: Naing A Lin CC Patel MR et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jun 08; Vol. 14 (6). Date of Electronic Publication: 2026 Jun 08.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Authors: Dummer R Sandhu S Miller WH Jr et al.

Source: Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 995-1013. Date of Electronic Publication: 2026 Mar 31.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process

Howard A. "Skip" Burris III, MD: an oncology pioneer reflects on patients, progress, and purpose.

Authors: Shaw ML Burris HA 3rd

Source: The American journal of managed care [Am J Manag Care] 2026 Feb; Vol. 32 (Spec. No. 2), pp. SP74-SP76.

Publication Type: Journal Article; Historical Article

Journal Info: Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care Subsets: MEDLINE

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Authors: Gounder M Johnson M Heist RS et al.

Source: Nature communications [Nat Commun] 2025 Jan 06; Vol. 16 (1), pp. 423. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Authors: Schram AM Naqash AR Haura EB et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4933-4943.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

Authors: Oh DY He AR Qin S et al.

Source: Journal of hepatology [J Hepatol] 2025 Nov; Vol. 83 (5), pp. 1092-1101. Date of Electronic Publication: 2025 May 15.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE

The evolving landscape of tissue-agnostic therapies in precision oncology.

Authors: Subbiah V Gouda MA Ryll B et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2024 Sep-Oct; Vol. 74 (5), pp. 433-452. Date of Electronic Publication: 2024 May 30.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Authors: Mayer EL Tayob N Ren S et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Feb; Vol. 204 (1), pp. 123-132. Date of Electronic Publication: 2023 Nov 29.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

Authors: Subbiah V Burris HA 3rd Kurzrock R

Source: Cancer [Cancer] 2024 Jan; Vol. 130 (2), pp. 186-200. Date of Electronic Publication: 2023 Nov 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.

Authors: Meric-Bernstam F Raghav KPS Sweeney CJ et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jul 15; Vol. 31 (14), pp. 2935-2944.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE